METHOD TO TREAT alpha-GALACTOSIDASE A DEFICIENCY

medicine, pathology. SUBSTANCE: the method deals with patients suffering alpha-galactosidase A (gal A) deficiency. Patient is introduced with a human cell genetically modified for superexpression and secretion of human alpha-gal A. The method, also, includes polypeptisis-coding DNA molecule which co...

Full description

Saved in:
Bibliographic Details
Main Authors TREKO DUGLAS A, UILL'JAMS MELANI D, KINOSITA KEHROL M, BOROVSKI MARIANN, DZHILLSPAJ FREHNSIS P, SELDEN RICHARD F
Format Patent
LanguageEnglish
Published 10.02.2002
Edition7
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES USING MICROORGANISMS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:medicine, pathology. SUBSTANCE: the method deals with patients suffering alpha-galactosidase A (gal A) deficiency. Patient is introduced with a human cell genetically modified for superexpression and secretion of human alpha-gal A. The method, also, includes polypeptisis-coding DNA molecule which contains alpha-gal A, purification method and therapeutic composition. EFFECT: higher efficiency of therapy. 12 cl, 13 dwg, 7 tbl
Bibliography:Application Number: RU19990107287